Also found in: Medical, Wikipedia.
H5N1Hemagglutinin Type 5 and Neuraminidase Type 1 (Avian Influenza A)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
H5N1 is an avian influenza virus that causes severe respiratory illness in birds.
In Egypt, highly pathogenic avian influenza subtype H5N1 virus was first reported in poultry in 2006 and was declared to be enzootic in 2008 (2,3).
This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Richt and his colleagues focused on the avian influenza virus subtype H5N1, a new strain most active in Indonesia, Egypt and other Southeast Asian and North African countries.
Along that route, H5N1 epidemics spread at a rate of 607.26 kilometers per month, close to the birds' migration speed of 573.19 km per month.
Following the unprecedented outbreak of highly pathogenic avian influenza (HPAI) H5N1 (here after H5N1) in 2005 at Qinghai Lake China the role of wild birds in the maintenance and transmission of H5N1 has been widely debated (Liu et al.
CAIRO - Egypt reported on Wednesday four new deaths from bird flu, taking to seven the number of people that the H5N1 virus has killed in the country so far in 2014.
10 October 2013 - A genomic analysis, performed by synthetic vaccines developer Replikins Ltd, has shown that the influenza strain H5N1 (bird flu) has the highest replikin counts among four other similar strains, including H3N2, H2N2, H1N1 and H7N9.
The H5N1 vaccine was found to be safe and well-tolerated and induced a solid immune response exceeding the three CHMP (Committee for Medicinal Products for Human Use) immunogenicity criteria for licensure of influenza vaccines.
The FDA's Vaccines and Related Biological Products Advisory Committee voted 14-0 that the influenza A (H5N1) Virus Monovalent Vaccine should be approved based on the safety and immune responses to the vaccine in clinical studies,
Singapore, May 29, 2012 - (ACN Newswire) - The close collaboration between scientists from the Experimental Therapeutics Centre (ETC) under the Agency for Science and Technology Research (A*STAR) and clinicians from Tan Tock Seng Hospital (TTSH) has enabled the successful development of the most comprehensive and rapid H5N1 bird flu test kit available to date.
Surveillance and isolation of HPAI H5N1 from wild mandarin ducks (Aix galericulata).